The agreement, which also includes a team of biotech executives, will see Bluebird Bio’s stockholders receive $3.00 per share ...
Krystal Biotech's VYJUVEK sees strong growth with $1B+ 2025 sales forecast. Check out why I rate KRYS as a Strong Buy and my ...
Bluebird Bio (NASDAQ:BLUE) stock in focus as company intends to go private in M&A deal with Carlyle Group (CG) & SK Capital. Read more here.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback